The reiteration of a Buy rating and maintenance of a $32 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong bullish sentiment towards Iovance Biotherapeutics. This endorsement is likely to positively influence investor perception and could lead to a short-term uptick in the stock's price, reflecting the analyst's confidence in the company's future performance.